Known targets — ChEMBL curated mechanism
ADRB1CDK4CDK6CHRM2CHRM3DPP4DRD2DRD3DRD4EGFRHRH1HTR1BHTR1DHTR1FHTR2AHTR2CHTR4SLC6A2SLC6A4
The experimentally established mechanism targets of Pimelic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 5/20 | 0.92 |
| ▸ | LMNA | P02545 | 4/20 | 0.92 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.92 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.92 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.71 |
| ▸ | GPR84 | Q9NQS5 | 8/20 | 0.71 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.71 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.71 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.69 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.69 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.69 |
| ▸ | PPARG | P37231 | 6/20 | 0.67 |
| ▸ | PPARD | Q03181 | 6/20 | 0.67 |
| ▸ | PPARA | Q07869 | 6/20 | 0.67 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.67 |
| ▸ | TLR2 | O60603 | 2/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.67 |
| ▸ | MEN1 | O00255 | 2/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Octanedioate SCHEMBL3852958 | 1.00 | TSHR (0.92) | TSHRLMNANFKB1PMP22SLC22A6 | |
| Sebacic Acid SCHEMBL20594219 | 1.00 | TSHR (0.92) | TSHRLMNANFKB1PMP22SLC22A6 | |
| Succinic Acid SCHEMBL28346539 | 1.00 | TSHR (0.92) | TSHRLMNANFKB1PMP22SLC22A6 | |
| Azelaic Acid SCHEMBL10456758 | 1.00 | TSHR (0.92) | TSHRLMNANFKB1PMP22SLC22A6 | |
| Sebacic Acid SCHEMBL8405057 | 1.00 | TSHR (0.92) | TSHRLMNANFKB1PMP22SLC22A6 | |
| Succinic Acid SCHEMBL28059863 | 1.00 | TSHR (0.92) | TSHRLMNANFKB1PMP22SLC22A6 | |
| Octanedioate SCHEMBL5800699 | 1.00 | TSHR (0.92) | TSHRLMNANFKB1PMP22SLC22A6 | |
| Octanedioate SCHEMBL28812368 | 0.96 | TSHR (0.86) | TSHRLMNANFKB1PMP22SLC22A6 | |
| Pimelic Acid SCHEMBL28069641 | 0.96 | TSHR (0.86) | TSHRLMNANFKB1PMP22SLC22A6 | |
| Octanedioate SCHEMBL28269347 | 0.96 | TSHR (0.86) | TSHRLMNANFKB1PMP22SLC22A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130158076-A1 | Methylene Urea Derivatives | MERCK PATENT GMBH (DE) | 2013-06-20 | — | — | US | disclosed |
| US-8410143-B2 | Methylene urea derivatives | MERCK PATENT GMBH (DE) | 2013-04-02 | — | — | US | disclosed |
| EP-2426122-A1 | Methylene urea derivative as RAF kinasse inhibitors | Merck Patent GmbH (DE) | 2012-03-07 | — | — | EP | disclosed |
| US-8003657-B2 | Heterocyclic substituted bisarylurea derivatives | MERCK PATENT GMBH (DE) | 2011-08-23 | — | — | US | disclosed |
| US-20090298885-A1 | METHYLENE UREA DERIVATIVES | MERCK PATENT GMBH (DE) | 2009-12-03 | — | — | US | disclosed |
| US-20090253688-A1 | Semicarbazide derivatives as kinase inhibitors | MERCK PATENT GMBH (DE) | 2009-10-08 | — | — | US | disclosed |
| US-7589112-B2 | Methylene urea derivatives | MERCK PATENT GMBH (DE) | 2009-09-15 | — | — | US | disclosed |
| US-20090215799-A1 | HETEROCYCLIC SUBSTITUTED BISARYLUREA DERIVATIVES | MERCK PATENT GMBH | 2009-08-27 | — | — | US | disclosed |
| US-20090124633-A1 | N-OXIDES OF HETEROCYCLIC SUBSTITUTED BISARYLUREAS FOR TREATING KINASE-MEDIATED DISEASES | MERCK PATENT GESELLSCHAFT (DE) | 2009-05-14 | — | — | US | disclosed |
| EP-2004631-A1 | N-OXIDES OF HETEROCYCLIC SUBSTITUTED BISARYLUREAS FOR TREATING KINASE-MEDIATED DISEASES | Merck Patent GmbH (DE) | 2008-12-24 | — | — | EP | disclosed |
| EP-1692110-A1 | DIACYLHYDRAZINE DERIVATIVES | MERCK PATENT GmbH (DE) | 2006-08-23 | — | — | EP | disclosed |
| WO-2006040056-A1 | HETEROCYCLIC SUBSTITUTED BISARYLUREA DERIVATIVES AS KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2006-04-20 | — | — | WO | disclosed |
| WO-2005082862-A2 | BENZIMIDAZOLYL DERIVATIVES AS KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2005-09-09 | — | — | WO | disclosed |
| WO-2005082858-A2 | ISOQUINOLINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2005-09-09 | — | — | WO | disclosed |
| WO-2005082853-A1 | SEMICARBAZIDE DERIVATIVES AS KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2005-09-09 | — | — | WO | disclosed |
| WO-2005075425-A2 | SUBSTITUTED BISARYLUREA DERIVATIVES AS KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2005-08-18 | — | — | WO | disclosed |
| EP-1562905-A2 | METHYLENE UREA DERIVATIVES AS RAF-KINASE INHIBITORS | MERCK PATENT GmbH (DE) | 2005-08-17 | — | — | EP | disclosed |
| WO-2005058832-A1 | DIACYLHYDRAZINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2005-06-30 | — | — | WO | disclosed |
| WO-2004037789-A2 | METHYLENE UREA DERIVATIVES AS RAF-KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2004-05-06 | — | — | WO | disclosed |
| US-20030176465-A1 | Cyclic amino acid derivatives | MERCK PATENT GMBH (DE) | 2003-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176465-A1 | Cyclic amino acid derivatives | F5, F11, F2 | SLC6A2 4552/4885TSHR 1006/4885LMNA 1708/4885 |
| US-20090298885-A1 | METHYLENE UREA DERIVATIVES | BRAF, RAF1, CMPK1 | SLC6A2 4644/4885TSHR 3305/4885LMNA 3748/4885 |
| US-20090124633-A1 | N-OXIDES OF HETEROCYCLIC SUBSTITUTED BISARYLUREAS FOR TREATING KINASE-MEDIATED DISEASES | ABL1, NME2, MAP3K1 | SLC6A2 3814/4885TSHR 2294/4885LMNA 1727/4885 |
| US-20090215799-A1 | HETEROCYCLIC SUBSTITUTED BISARYLUREA DERIVATIVES | ABL1, BTK, PRKACA | SLC6A2 3991/4885TSHR 1315/4885LMNA 2389/4885 |
| US-20130158076-A1 | Methylene Urea Derivatives | BRAF, RAF1, CMPK1 | SLC6A2 4644/4885TSHR 3305/4885LMNA 3748/4885 |
| US-20090253688-A1 | Semicarbazide derivatives as kinase inhibitors | MAP3K1, MAP3K6, MAP3K2 | SLC6A2 3035/4885TSHR 1520/4885LMNA 2512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.